## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
1. Name and Address of Reporting Person * PARKER H STEWART				2. Issuer Name and Ticker or Trading Symbol ACHIEVE LIFE SCIENCES, INC. [ACHV]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)XDirector10% Owner								
19820 No		(First) EEK PARKWA	Y, SUITE 201	3. Date 08/01/		arliest Tra 7	ansac	ction (M	/lonth/D	ay/Ye	ear)			Officer (give	title below)	Oth	ner (specify l	pelow)	
ВОТНЕІ	LL, WA 98	(Street)		4. If An	nend	ment, Da	te Or	iginal F	Filed(Mor	nth/Day	y/Year)		_X_ Fo	orm filed by (	One Reporting F	Filing(Check Person Reporting Person		Line)	
(Cit		(State)	(Zip)			7	Γable	e I - No	n-Deriv	vative	Securities	s Acqui	ired, l	Disposed	of, or Benef	icially Own	ed		
(Instr. 3) Date			2. Transaction Date (Month/Day/Yea			ned Date, if	3. Transaction Code (Instr. 8)		ion 4.	4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		of (D) Own Trans		Amount of Securities Beneficially by Manuel Following Reported ransaction(s) nstr. 3 and 4)		Ownership of Form:		7. Nature of Indirect Beneficial Ownership	
						.,,	С	ode	V A	mour	(A) or (D)	Price		,			or Indire (I) (Instr. 4)	ct (In	
Common	Stock												1,13	6 <sup>(1)</sup>			D		
Reminder:	Report on a s	separate line for each		- Deriva	ıtive	Securitie	es Ac	P ir a equired	ersons this for currer	orm antly v	are not re valid OMB f, or Benef	quired contr	l to re ol nu	espond u mber.		on contain form displ		EC 147	74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4.	tion	5. Numb	er ative es d (A) osed	6. Da Expir (Mon	te Exerc	cisable ate		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number Derivative Securities Beneficially Owned Following Reported Transaction	Own Form Deriv Secu Direct or Ind(s) (I)	of vative rity: et (D) direct	11. Naturo of Indirec Beneficia Ownershi (Instr. 4)	
				Code	V	(A)	(D)		cisable	Ex <sub>I</sub> Dat	oiration te	Title		Amount or Number of Shares		(Instr. 4)	(Instr	. 4)	
Stock Option (right to buy)	\$ 4.57	08/01/2017		A		11,000		08/0	1/2018	8 08	/01/2027	Com Sto		11,000	\$ 0	11,000	1	)	
Stock Option (right to buy)	\$ 156.2 (1)								<u>(2)</u>	06	/08/2020	Com Sto		67 <u>(1)</u>		67	1	)	
Stock Option (right to buy)	\$ 196.02 (1)								<u>(2)</u>	05/	/26/2021	Com		318 (1)		318	]	)	
Stock Option (right to buy)	\$ 138.16 (1)								<u>(2)</u>	05/	/31/2022	Com Sto	mon ock	363 (1)		363	]	)	
Stock Option (right to buy)	\$ 118.03 (1)								(2)	05,	/24/2023	Com Sto		454 <u>(1)</u>		454	]	)	
Stock Option (right to buy)	\$ 39.82 (1)								(2)	06	/05/2024	Com		454 (1)		454	]	)	

Stock Option (right to buy)	\$ 20.79 (1)			(2)	05/21/2025	Common Stock	454 (1)	454	D	
Stock Option (right to buy)	\$ 11 <del>(1)</del>			(2)	05/26/2026	Common Stock	2,045 (1)	2,045	D	

#### **Reporting Owners**

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
PARKER H STEWART 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL, WA 98011	X							

### **Signatures**

Sandra Thomson Attorney-in-fact for Stewart Parker	08/03/2017		
**Signature of Reporting Person	Date		

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects the 11-for-1 reverse stock split effected on August 1, 2017 immediately following the merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc.
- (2) The options are fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.